Expertise in
35
conditions

Dr. Preston Steen

Internal Medicine
Sanford Clinic North
820 4th St N, 
Fargo, ND 
Clinical Trials:Currently Recruiting for 3 Trials
Expertise in
35
conditions
Sanford Clinic North
820 4th St N, 
Fargo, ND 

Overview

Preston Steen is an Internal Medicine provider practicing medicine in Fargo, North Dakota.

Dr. Steen is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Tissue Biopsy, and Prostatectomy.

He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 172 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in ND

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

HealthPartners
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO

Locations

Sanford Clinic North
820 4th St N, Fargo, ND 58102

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

169 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Mitomycin
Study Phase: Phase 2
A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin
Study Phase: Phase 3
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Drug
Study Drugs: Darolutamide, Goserelin acetate, Leuprolide acetate, Triptorelin
Study Phase: Phase 3
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Biological, Drug
Study Drugs: Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab
Study Phase: Phase 2
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Enrollment Status: Active_not_recruiting
Publish Date: June 18, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 3
View 7 Less Clinical Trials

13 Total Publications

Improving Rural Clinical Trial Enrollment: Recommendations From the Rural Health Working Group of the Alliance Clinical Trials Network.
Improving Rural Clinical Trial Enrollment: Recommendations From the Rural Health Working Group of the Alliance Clinical Trials Network.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 27, 2024
Similar Doctors
Expertise in
30
conditions
Dr. Lindsey Dahl
Internal Medicine | Geriatrics
Expertise in
30
conditions
Dr. Lindsey Dahl
Internal Medicine | Geriatrics

Sanford Southpointe Clinic

2400 32nd Ave. S., 
Fargo, ND 
 (3.4 miles away)
701-234-2000
Languages Spoken:
English
See accepted insurances

Lindsey Dahl, MD, is a fellowship-trained geriatrician who specializes in geriatric and internal medicine with a special interest in fall prevention, exercise and training future doctors. Dr. Dahl is highly rated in 30 conditions, according to our data. Her clinical expertise encompasses Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, Hypertension, and Melorheostosis. Dr. Dahl is board certified in American Board Of Internal Medicine American Board Of Internal Medicine: Geriatrics.

Expertise in
20
conditions
Dr. Michael Sheldon
Internal Medicine
Expertise in
20
conditions
Dr. Michael Sheldon
Internal Medicine

Essentia Health-South University Clinic (Fargo)

1702 University Dr S, 
Fargo, ND 
 (1.7 miles away)
701-205-0094
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Sheldon is a primary care provider, practicing in Internal Medicine in Fargo, North Dakota. Dr. Sheldon is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Hypertension, Glucocorticoid-Remediable Aldosteronism, Familial Hypertension, and Maturity Onset Diabetes of the Young.

Expertise in
9
conditions
Dr. Michael Sand
Internal Medicine
Expertise in
9
conditions
Dr. Michael Sand
Internal Medicine

Sanford Moorhead Campus

4000 28th Ave. S., 
Moorhead, MN 
 (4.1 miles away)
701-234-3200
Languages Spoken:
English
See accepted insurances

Michael Sand is a primary care provider, practicing in Internal Medicine in Moorhead, Minnesota. Dr. Sand is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Hypertension, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, and Memory Loss. Dr. Sand is board certified in American Board Of Internal Medicine.

Frequently Asked Questions about Dr. Preston Steen

How do I make an appointment with Dr. Preston Steen?

You can book an appointment with Dr. Preston Steen by calling their office at 320-839-2502. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Preston Steen a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Preston Steen is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Preston Steen specialize in?

While Dr. Preston Steen is a Internal Medicine, they have specific expertise in Colorectal Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Preston Steen participate in research or clinical trials?

Yes. Dr. Preston Steen has published 13 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Preston Steen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Preston Steen accept my insurance?

Dr. Preston Steen accepts most major insurance plans, including HealthPartners and Medica. We recommend calling the office directly at 320-839-2502 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Steen's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 28 Advanced Conditions
    View All 103 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile